IP Library Granted Patent US 7,179,592
Granted Patent B2
US 7,179,592 · App. 09/920,435 · Granted Feb 20, 2007

Size-exclusion-based extraction of affinity ligands and active compounds from natural samples

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,179,592
App. No.
09/920,435
Granted
Feb 20, 2007
Kind
B2
Abstract

The invention encompasses an improved, rapid, size-exclusive method for screening for small molecular weight ligands that bind specifically to a protein target, using size-exclusion separation, ultrafiltration, and mass spectrometry.

Claims (29)

1. A method of screening a sample of complex biological material for an affinity ligand that binds to a protein target, comprising:

(1) mixing a protein target and a sample of complex biological material in solution to form a reaction mixture;

(2) incubating the reaction mixture wider conditions allowing complex formation by the target and any target-binding ligand present in the sample;

(3) passing the reaction mixture through a first size-exclusion medium that removes from the reaction mixture any small molecular weight compounds each having a molecular weight less than a first preset value;

(4) subjecting the size-excluded reaction mixture from step (3) to conditions promoting dissociation of any ligand/target complex into free ligand and free target; and

(5) passing the reaction mixture resulting from step (4) through a second size exclusion medium that removes from the reaction mixture any molecule larger than a second preset value.

2. The method of claim 1 , wherein the first size-exclusion medium removes molecules having a molecular weight of about 2,000 daltons or less.

3. The method of claim 1 , wherein the first size-exclusion medium removes molecules having a molecular weight of about 1,500 daltons or less.

4. The method of claim 1 , wherein the first size-exclusion medium comprises a gel filtration or size exclusion HPLC column.

5. The method of claim 1 , wherein step (4) comprises adding to the size-excluded mixture from step (3), a solution comprising an organic solvent and an organic acid.

6. The method according to claims 1 , 4 , or 5 , wherein the second size-exclusion medium comprises an ultrafiltration membrane.

7. The method according to claims 1 , 4 , or 5 , wherein the second size-exclusion medium removes from the reaction mixture, molecules having a molecular weight of about 10,000 daltons or more.

8. The method according to claims 1 , 4 , or 5 , wherein the second size-exclusion medium removes from the reaction mixture, molecules having a molecular weight of about 3,000 daltons or more.

9. The method according to claims 1 , 4 , or 5 , wherein the second size-exclusion medium removes from the reaction mixture, molecules having a molecular weight of about 2,000 daltons or more.

10. The method of claim 6 , wherein the ultrafiltration membrane removes from the reaction mixture, molecules having a molecular weight of about 10,000 daltons or more.

11. The method of claim 6 , wherein the ultrafiltration membrane removes from the reaction mixture, molecules having a molecular weight of about 3,000 daltons or more.

12. The method of claim 6 , wherein the ultrafiltration membrane removes from the reaction mixture, molecules having a molecular weight of about 2,000 daltons or more.

13. The method according to claims 1 , 4 , or 5 , further comprising, after step (5):

(6) subjecting the reaction mixture resulting from step (5), to at least one structural or functional analysis.

14. The method according to claim 13 , further comprising:

(7) comparing the analytical results of step (6) with a reference standard.

15. The method of claim 14 , wherein the reference standard comprises the analytical results of subjecting either a sample of the protein target alone or a mixture of the protein target with a non-target-binding natural sample, to steps (2)-(6).

16. The method of claim 13 , wherein the at least one analysis in step (6) comprises a member selected from the group consisting of mass spectrometry analysis; liquid chromatography; liquid chromatography coupled on-line with mass spectrometry analysis; infrared spectroscopy; nuclear magnetic resonance; an alternative binding assay; a biochemical assay; a cell-based reporter assay; and an ELISA-based assay.

17. The method according to claim 1 , 4 , or 5 , further comprising, in step (1), including a known competitive ligand that binds to the target in the reaction mixture prior to step (2).

18. The method of claim 17 , wherein the concentrations of the known competitive ligand and the target are approximately equimolar.

19. The method of claim 17 , wherein the known competitive ligand concentration is within a range of approximately twice to 10 times the target concentration.

20. The method of claim 17 , wherein the known competitive ligand concentration is approximately 5 times the target concentration.

21. The method of claim 17 , further comprising the step (7) of comparing the analytical results of step (6) with a reference standard.

22. The method of claim 21 , wherein the reference standard comprises the analytical results of subjecting a mixture of the protein target and the known competive ligand, in the absence of any other target-binding ligand, to steps (2)-(6).

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Jun 10, 2009
From: YA GLOBAL INVESTMENTS, L.P.
To: TRIAD BIOTHERAPEUTICS, INC.; ADVANCED VIRAL RESEARCH CORP.
Reel/Frame 022804/0412 →
SECURITY AGREEMENT Recorded May 20, 2009
From: BBM HOLDINGS, INC.
To: YA GLOBAL INVESTMENTS, L.P.
Reel/Frame 022708/0679 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 022542 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE OWNERSHIP TRANSFERED FROM ADVANCED VIRAL RESEARCH CORP. AND TRIAD BIOTHERAPEUTICS, INC. TO BBM HOLDINGS, INC. Recorded Apr 30, 2009
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: BBM HOLDINGS, INC.
Reel/Frame 022629/0569 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR/ASSIGNEE NAMES PREVIOUSLY RECORDED ON REEL 022510 FRAME 0187. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNORS ARE ADVANCED VIRAL RESEARCH CORP. AND TRIAD BIOTHERAPEUTICS, INC., AND THE ASSIGNEE IS YA GLOBAL INVESTMENTS, L.P. Recorded Apr 14, 2009
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: YA GLOBAL INVESTMENTS, L.P. (F/K/A CORNELL CAPITAL PARTNERS, L.P.)
Reel/Frame 022542/0001 →
FORECLOSURE BY THIRD PARTY Recorded Apr 6, 2009
From: YA GLOBAL INVESTMENTS, L.P. (F/K/A CORNELL CAPITAL PARTNERS, L.P.)
To: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
Reel/Frame 022510/0187 →
SECURITY AGREEMENT Recorded Dec 14, 2007
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: YA GLOBAL INVESTMENTS, LP
Reel/Frame 020403/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2007
From: GULLO, VINCENT P.; HUGHES, DALLAS E.
To: TRIAD BIOTHERAPEUTICS, INC.
Reel/Frame 020234/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2007
From: CETEK CORPORATION
To: GULLO, VINCENT; HUGHES, DALLAS
Reel/Frame 019407/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2002
From: DUNAYEVSKIY, YURIY M.; HUGHES, DALLAS E.; WEISKOPF, ANDREW S.
To: CETEK CORPORATION
Reel/Frame 012444/0895 →